Javier Villaseca

Javier Villaseca

Auto-generated profile, based on publicly available information

Javier Villaseca

Department of Health Economics, Weber, Madrid, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2024 in Applied Health Economics and Health Policy
Verified
Journal Article
Closed access
PDF file
NZNéboa Zozaya
Néboa Zozaya
JVJavier Villaseca
Javier Villaseca
IFIrene Fernández
Irene Fernández
FAFernando Abdalla
Fernando Abdalla
BCBenito Cadenas-Noreña
Benito Cadenas-Noreña
ÁHÁlvaro Hidalgo-Vega
Álvaro Hidalgo-Vega

8 January 2022 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
NZNéboa Zozaya
Néboa Zozaya
JVJ. Villaseca
J. Villaseca
FAFernando Abdalla
Fernando Abdalla
MCM. A. Calleja
M. A. Calleja
JDJosé Luís Díez-Martín
José Luís Díez-Martín
AHA. Hidalgo-Vega
A. Hidalgo-Vega
CAR-T cell therapy represents a therapeutic revolution in the prognosis and treatment of patients with certain types of hematological cancer. However, they also pose new challenges in the healthcare, regulatory and financial fields. The aim of the RET-A project was to undertake a strategic reflection on the management of CAR-T therapies within the Spanish National Health System, to agree on recommendations that will help to better deal with the new context introduced by these cell therapies in the present and in the future. This think tank involved 40 key agents and opinion leaders. The experts identified three great challenges for implementing advanced therapies in Spain: therapeutic individualisation, with a multidisciplinary approach; acceleration of access times, by minimizing bureaucracy; and increase in the number of centers qualified to manage the CAR-T therapies in the NHS. The experts agreed on the ideal criteria for designating those qualified centers. They also agreed on a comprehensive CAR-T care pathway with the timings and roles which would ideally be involved in each part of the process.

3 April 2020 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
NZNéboa Zozaya
Néboa Zozaya
BRB. Alcalá Revilla
B. Alcalá Revilla
PMP. Arrazola Martínez
P. Arrazola Martínez
JBJ. R. Chávarri Bravo
J. R. Chávarri Bravo
IEI. Cuesta Esteve
I. Cuesta Esteve
AHA. Hidalgo-Vega
A. Hidalgo-Vega
Objective: To advance the development of an ideal and sustainable framework agreement for the public procurement of vaccines in Spain, and to agree on the desirable award criteria and their relative weight. Methods: A multidisciplinary committee of seven health-care professionals and managers developed a partial multi-criteria decision analysis to determine the award criteria that should be considered and their specific weights for the public procurement of routine vaccines and seasonal influenza vaccines, considering their legal viability. A re-test of the results was carried out. The current situation was analyzed through 118 tender specifications and compared to the ideal framework. Results: Price is the prevailing award criterion for the public procurement of both routine (weighting of 60% versus 40% for all other criteria) and influenza (36% versus 64%) vaccines. Ideally, 22 criteria should be considered for routine vaccines, grouped and weighted into five domains: efficacy (weighting of 29%), economic aspects (27%), vaccine characteristics (22%), presentation form and packaging (13%), and others (9%). Per criteria set, price was the most important criterion (22%), followed by effectiveness (9%), and composition/formulation (7%). Regarding influenza vaccines, 20 criteria were selected, grouped, and weighted: efficacy (29%), economic aspects (25%), vaccine characteristics (20%), presentation form and packaging (16%), and others (11%). Per criteria set, price was also the most relevant criterion (19%), followed by composition/formulation (8%), and effectiveness (8%). Conclusions: Contrary to the current approach, technical award criteria should prevail over economic criteria in an ideal and sustainable framework agreement for the public procurement of vaccines.